LAVAL, QC, May 14, 2020 /CNW/ - Crescita Therapeutics
Inc. (TSX: CTX) (OTC US: CRRTF) ("Crescita" or the
"Company"), a growth-oriented, innovation-driven Canadian
commercial dermatology company with in-house research &
development ("R&D") and manufacturing capabilities, today
announced the voting results from its 2020 Annual General Meeting
of Shareholders held at its corporate headquarters in Laval, Québec.
The detailed results of the votes received by proxy are as
follows:
Election of Directors
|
Director
Nominees
|
NUMBER OF
SHARES
|
PERCENTAGE OF
VOTES CAST
|
|
FOR
|
WITHHELD
|
FOR
|
WITHHELD
|
|
Daniel N.
Chicoine
|
2,821,612
|
65,758
|
97.7%
|
2.3%
|
|
David A.
Copeland
|
2,817,667
|
69,703
|
97.6%
|
2.4%
|
|
Anthony E.
Dobranowski
|
2,853,668
|
33,702
|
98.8%
|
1.2%
|
|
John C.
London
|
2,743,472
|
143,898
|
95.0%
|
5.0%
|
|
Dr. Jean-François
Tremblay
|
2,858,249
|
28,121
|
99.0%
|
1.0%
|
|
Thomas
Schlader
|
2,858,828
|
28,542
|
99.0%
|
1.0%
|
Appointment of External Auditors
|
Outcome
|
NUMBER OF
SHARES
|
PERCENTAGE OF
VOTES CAST
|
|
FOR
|
WITHHELD
|
FOR
|
WITHHELD
|
|
Ernst & Young LLP
reappointed
|
3,020,568
|
16,739
|
99.4%
|
0.6%
|
About Crescita
Therapeutics Inc.
Crescita (TSX: CTX and
OTC US: CRRTF) is a growth-oriented, innovation-driven
Canadian commercial dermatology company with in-house R&D and
manufacturing capabilities. The Company offers a portfolio of
non-prescription skincare products and early to commercial stage
prescription drug products and owns multiple proprietary drug
delivery platforms that support the development of patented
formulations that can facilitate the delivery of active ingredients
into or through the skin.
Supported by a sales force covering all of Canada and executing its Business to Business
to Consumer marketing approach, Crescita sells its non-prescription
skincare products domestically through spas, medispas, and medical
clinics, as well as internationally, through distributors and an
e-commerce platform.
Crescita's predecessor company, Nuvo Research Inc., developed a
prescription product called Pliaglis®, that utilizes the Company's
proprietary phase-changing topical cream Peel technology, a
part of the DuraPeel™ family, which are self-occluding,
film-forming cream/gel formulations, that provide extended release
delivery of the active ingredients to the site of application.
Pliaglis is a topical local anesthetic cream that provides safe and
effective local dermal analgesia on intact skin prior to
superficial dermatological procedures. The product is currently
approved in over 25 different countries and sold by commercial
partners in the U.S., Italy and
Brazil, and sold in Canada by the Company.
Crescita's expertise in product formulation and development can
be leveraged in combination with its patented transdermal delivery
technologies to develop and manufacture creams, liquids, gels
ointments and serums under its contract development and
manufacturing organization ("CDMO") infrastructure. The Company
operates out of a 50,000-square-foot facility located in
Laval, Québec, which produces a
significant part of its non-prescription skincare products, such as
LDR, Pro-Derm and Alyria. Formulations manufactured by or for
Crescita include cosmetics, natural health products ("NHP") and
products with Drug Identification Numbers ("DIN"). For additional
information, please visit www.crescitatherapeutics.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/crescita-therapeutics-announces-the-results-of-its-annual-general-meeting-of-shareholders-301059357.html
SOURCE Crescita Therapeutics Inc.